who says the Pill Works Well Against Omicron Variant

American drugmaker Pfizer said on Tuesday that his therapeutic test pill COVID-19 appeared to be effective against the Omicron variant that was rapidly spreading. The company said its 2,250 study found that the drug reduced sleep and death by about 90 percent in high-risk adults. Full results came from those who took the pill within three to five days showing symptoms of COVID-19. In a laboratory test, Pfizer said the drug also produces better results when compared to the Omicron variant. Pfizer tested the antiretroviral drug against the man-made version of the essential protein Omicron that it uses to make itself. The U.S. The Food and Drug Administration is expected to decide soon whether to approve the Pfizer pill and another from Merck for treatment. After strong initial results, Merck said last month its pill reduced sleepiness and mortality by only 30 percent. Authorized treatment currently requires injections from health care professionals. But the pill can be taken at home and is easy to ship worldwide. Screening among low-risk adults Pfizer said it is also testing its pill in healthy adults, including vaccinated. Partial results showed that the pill did not reduce the symptoms of COVID-19 for four days during or after treatment. However, the company said the pill reduced the sleepiness of healthy but uninvited adults by about 70 percent. A team of independent medical experts reviewed the data and advised Pfizer to continue research to get the full results. Rochelle Walensky is a U.S. director. Centers for Disease Control and Prevention. He told NBC television news program that the best protection for COVID-19 is still a target followed by another shotgun called a booster. Omicron vaccine In the United States, about 800,000 Americans died during the COVID-19 violence. The latest rise in mortality comes from the Delta variety. But Omicron variants are rapidly spreading in some parts of the U.S. and worldwide. The Omicron was first identified in South Africa and neighboring Botswana in November. Diversity has now created 90% of new diseases in South Africa. On Tuesday, the South African Medical Research Council and Discovery Health, a health insurance company, released their study on the Pfizer-BioNTech COVID-19 vaccine against Omicron. Studies have shown that people who have received a double dose of the Pfizer-BioNTech vaccine appear to have only 33 percent protection against infection, compared to those who have not been vaccinated. The vaccine has been shown to have a very high immunity, about 80 percent, to diseases from a variety of earlier species such as Delta. However, the gun provided 70 percent protection against hospitalization. This study did not look at those with booster shots as they are not widely available in South Africa. The Associated Press reports that international scientists are still studying Omicron and officials will need to consider that in making decisions.The Associated Press reports that international scientists are still studying Omicron and officials will need to consider that in making decisions.The Associated Press reports that international scientists are still studying Omicron and officials will need to consider that in making decisions.